Federico Alberici1, Rona M Smith2, Rachel B Jones2, Darren M Roberts2, Lisa C Willcocks2, Afzal Chaudhry2, Kenneth G C Smith3, David R W Jayne2. 1. Department of Medicine, University of Cambridge School of Clinical Medicine, Vasculitis and Lupus Service, Addenbrooke's Hospital, Cambridge, UK, Department of Clinical and Experimental Medicine, University of Parma, Italy and Cambridge Institute for Medical Research, University of Cambridge, Cambridge Biomedical Campus, Cambridge, UK Department of Medicine, University of Cambridge School of Clinical Medicine, Vasculitis and Lupus Service, Addenbrooke's Hospital, Cambridge, UK, Department of Clinical and Experimental Medicine, University of Parma, Italy and Cambridge Institute for Medical Research, University of Cambridge, Cambridge Biomedical Campus, Cambridge, UK Department of Medicine, University of Cambridge School of Clinical Medicine, Vasculitis and Lupus Service, Addenbrooke's Hospital, Cambridge, UK, Department of Clinical and Experimental Medicine, University of Parma, Italy and Cambridge Institute for Medical Research, University of Cambridge, Cambridge Biomedical Campus, Cambridge, UK federico.alberici@gmail.com. 2. Department of Medicine, University of Cambridge School of Clinical Medicine, Vasculitis and Lupus Service, Addenbrooke's Hospital, Cambridge, UK, Department of Clinical and Experimental Medicine, University of Parma, Italy and Cambridge Institute for Medical Research, University of Cambridge, Cambridge Biomedical Campus, Cambridge, UK Department of Medicine, University of Cambridge School of Clinical Medicine, Vasculitis and Lupus Service, Addenbrooke's Hospital, Cambridge, UK, Department of Clinical and Experimental Medicine, University of Parma, Italy and Cambridge Institute for Medical Research, University of Cambridge, Cambridge Biomedical Campus, Cambridge, UK. 3. Department of Medicine, University of Cambridge School of Clinical Medicine, Vasculitis and Lupus Service, Addenbrooke's Hospital, Cambridge, UK, Department of Clinical and Experimental Medicine, University of Parma, Italy and Cambridge Institute for Medical Research, University of Cambridge, Cambridge Biomedical Campus, Cambridge, UK Department of Medicine, University of Cambridge School of Clinical Medicine, Vasculitis and Lupus Service, Addenbrooke's Hospital, Cambridge, UK, Department of Clinical and Experimental Medicine, University of Parma, Italy and Cambridge Institute for Medical Research, University of Cambridge, Cambridge Biomedical Campus, Cambridge, UK Department of Medicine, University of Cambridge School of Clinical Medicine, Vasculitis and Lupus Service, Addenbrooke's Hospital, Cambridge, UK, Department of Clinical and Experimental Medicine, University of Parma, Italy and Cambridge Institute for Medical Research, University of Cambridge, Cambridge Biomedical Campus, Cambridge, UK.
Abstract
OBJECTIVE: ANCA-associated vasculitis (AAV) is characterized by a chronic relapsing course. Rituximab (RTX) is an effective maintenance treatment; however, the long-term outcomes after its discontinuation are unclear. The aim of this study was to explore the long-term outcomes of AAV patients treated with repeat-dose RTX maintenance therapy. METHODS: AAV patients receiving a RTX treatment protocol consisting of an induction and maintenance phase were included. For initial remission induction, RTX was dosed at 1 g every 2 weeks or 375 mg/m(2) weekly for 4 consecutive weeks and for remission maintenance at 1 g every 6 months for 24 months. At the first RTX administration, ongoing immunosuppressives were withdrawn. RESULTS: Sixty-nine patients were identified, 67 of whom were failing other therapies. Nine relapsed during the RTX treatment protocol; however, all 69 were in remission at the end of the maintenance phase on a median prednisolone dose of 2.5 mg/day and 9% were receiving additional immunosuppression. During subsequent observation, 28 patients relapsed a median of 34.4 months after the last RTX infusion. Risk factors for relapse were PR3-associated disease (P = 0.039), B cell return within 12 months of the last RTX infusion (P = 0.0038) and switch from ANCA negativity to positivity (P = 0.0046). Two patients died and two developed severe hypogammaglobulinaemia. CONCLUSION: This study supports the efficacy and safety of a fixed-interval RTX maintenance regimen in relapsing/refractory AAV. Relapses after discontinuation of maintenance therapy did occur, but at a lower rate than after a single RTX induction course. PR3-associated disease, the switch from ANCA negative to positive and the return of B cells within 12 months of the last RTX administration were risk factors for further relapse.
OBJECTIVE: ANCA-associated vasculitis (AAV) is characterized by a chronic relapsing course. Rituximab (RTX) is an effective maintenance treatment; however, the long-term outcomes after its discontinuation are unclear. The aim of this study was to explore the long-term outcomes of AAV patients treated with repeat-dose RTX maintenance therapy. METHODS: AAV patients receiving a RTX treatment protocol consisting of an induction and maintenance phase were included. For initial remission induction, RTX was dosed at 1 g every 2 weeks or 375 mg/m(2) weekly for 4 consecutive weeks and for remission maintenance at 1 g every 6 months for 24 months. At the first RTX administration, ongoing immunosuppressives were withdrawn. RESULTS: Sixty-nine patients were identified, 67 of whom were failing other therapies. Nine relapsed during the RTX treatment protocol; however, all 69 were in remission at the end of the maintenance phase on a median prednisolone dose of 2.5 mg/day and 9% were receiving additional immunosuppression. During subsequent observation, 28 patients relapsed a median of 34.4 months after the last RTX infusion. Risk factors for relapse were PR3-associated disease (P = 0.039), B cell return within 12 months of the last RTX infusion (P = 0.0038) and switch from ANCA negativity to positivity (P = 0.0046). Two patients died and two developed severe hypogammaglobulinaemia. CONCLUSION: This study supports the efficacy and safety of a fixed-interval RTX maintenance regimen in relapsing/refractory AAV. Relapses after discontinuation of maintenance therapy did occur, but at a lower rate than after a single RTX induction course. PR3-associated disease, the switch from ANCA negative to positive and the return of B cells within 12 months of the last RTX administration were risk factors for further relapse.
Authors: John H Stone; Peter A Merkel; Robert Spiera; Philip Seo; Carol A Langford; Gary S Hoffman; Cees G M Kallenberg; E William St Clair; Anthony Turkiewicz; Nadia K Tchao; Lisa Webber; Linna Ding; Lourdes P Sejismundo; Kathleen Mieras; David Weitzenkamp; David Ikle; Vicki Seyfert-Margolis; Mark Mueller; Paul Brunetta; Nancy B Allen; Fernando C Fervenza; Duvuru Geetha; Karina A Keogh; Eugene Y Kissin; Paul A Monach; Tobias Peikert; Coen Stegeman; Steven R Ytterberg; Ulrich Specks Journal: N Engl J Med Date: 2010-07-15 Impact factor: 91.245
Authors: Rona M Smith; Rachel B Jones; Mary-Jane Guerry; Simona Laurino; Fausta Catapano; Afzal Chaudhry; Kenneth G C Smith; David R W Jayne Journal: Arthritis Rheum Date: 2012-11
Authors: Rodrigo Cartin-Ceba; Jason M Golbin; Karina A Keogh; Tobias Peikert; Marta Sánchez-Menéndez; Steven R Ytterberg; Fernando C Fervenza; Ulrich Specks Journal: Arthritis Rheum Date: 2012-11
Authors: J C Jennette; R J Falk; K Andrassy; P A Bacon; J Churg; W L Gross; E C Hagen; G S Hoffman; G G Hunder; C G Kallenberg Journal: Arthritis Rheum Date: 1994-02
Authors: Richard Watts; Suzanne Lane; Thomas Hanslik; Thomas Hauser; Bernhard Hellmich; Wenche Koldingsnes; Alfred Mahr; Mårten Segelmark; Jan W Cohen-Tervaert; David Scott Journal: Ann Rheum Dis Date: 2006-08-10 Impact factor: 19.103
Authors: Joanna Robson; Helen Doll; Ravi Suppiah; Oliver Flossmann; Lorraine Harper; Peter Höglund; David Jayne; Alfred Mahr; Kerstin Westman; Raashid Luqmani Journal: Ann Rheum Dis Date: 2013-11-15 Impact factor: 19.103
Authors: Jan Henrik Schirmer; Peer M Aries; Kirsten de Groot; Bernhard Hellmich; Julia U Holle; Christian Kneitz; Ina Kötter; Peter Lamprecht; Ulf Müller-Ladner; Eva Reinhold-Keller; Christof Specker; Michael Zänker; Frank Moosig Journal: Z Rheumatol Date: 2017-11 Impact factor: 1.372
Authors: Joanna C Robson; Gunnar Tomasson; Nataliya Milman; Sue Ashdown; Annelies Boonen; George C Casey; Peter F Cronholm; David Cuthbertson; Jill Dawson; Haner Direskeneli; Ebony Easley; Tanaz A Kermani; John T Farrar; Don Gebhart; Georgia Lanier; Raashid A Luqmani; Alfred Mahr; Carol A McAlear; Jacqueline Peck; Beverley Shea; Judy A Shea; Antoine G Sreih; Peter S Tugwell; Peter A Merkel Journal: J Rheumatol Date: 2017-09-01 Impact factor: 4.666
Authors: Lynn A Fussner; Amber M Hummel; Darrell R Schroeder; Francisco Silva; Rodrigo Cartin-Ceba; Melissa R Snyder; Gary S Hoffman; Cees G M Kallenberg; Carol A Langford; Peter A Merkel; Paul A Monach; Philip Seo; Robert F Spiera; E William St Clair; Nadia K Tchao; John H Stone; Ulrich Specks Journal: Arthritis Rheumatol Date: 2016-07 Impact factor: 10.995